Tech Company Financing Transactions
Autobahn Therapeutics Funding Round
Newpath Partners, Canaan Partners and Insight Venture Partners participated in a $100 million Series C venture round for Autobahn Therapeutics. The financing round closed on 7/25/2024.
Transaction Overview
Company Name
Announced On
7/25/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to commence two Phase 2 clinical trials for its lead program, ABX-002, a potent and selective thyroid hormone beta receptor (TRß) agonist that was well-tolerated and demonstrated CNS target engagement in a Phase 1 study.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9880 Campus Point Dr.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Finney
Chief Scientific Officer
Brian Stearns
President
Keith Lenden
Vice President
Chan Beals
Vice President
Deidre MacKenna
VP - Administration
John Borkholder
VP - Operations
Christine Maurer
Browse more venture capital transactions:
Prev: 7/25/2024: HASH venture capital transaction
Next: 7/25/2024: Navigantis venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs